![]() ![]() BOTOX ® provides an evidence-based dosing strategy to meet the clinical needs of providers and their patients." Brin, M.D., Senior Vice President, Chief Scientific Officer, BOTOX ® & Neurotoxins, AbbVie. "This label expansion not only adds to our rich history in neurotoxin science, but also reinforces the role of BOTOX ® in upper limb spasticity treatment. "Today's announcement is especially important because spasticity is a disabling neurological condition that can have a significant impact on a patient's quality of life," said Mitchell F. The label now includes the use of ultrasound as a muscle localization technique in adult spasticity. Food and Drug Administration (FDA) has approved a label expansion of BOTOX ® to include eight new muscles for the treatment of upper limb spasticity in adults. The new muscles for treatment include additional muscles of the elbow and forearm (brachialis, brachioradialis, pronator teres, and pronator quadratus), as well as intrinsic hand muscles (lumbricals and interossei) and thumb muscles (flexor pollicis brevis and opponens pollicis). NORTH CHICAGO, Ill., J/PRNewswire/ - Allergan, an AbbVie (NYSE: ABBV) company, today announced that the U.S.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |